Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.

Document Type

Article

Publication Date

10-2024

Identifier

DOI: 10.1002/pbc.31213

Abstract

High-dose methotrexate (HD-MTX) is used in the treatment of children with central nervous system (CNS) tumors; however, toxicity information is limited. We characterized toxicities following 102 administrations of HD-MTX (4.6-13.5 g/m2) infused over 4 or 24 h in 38 children with a CNS tumor before 6 years of age (2010-2020). Delayed clearance of methotrexate occurred following 24% of infusions. Common Terminology Criteria for Adverse Events v5 grade 2-3 mucositis was observed in 47% of individuals, Grade 4 neutropenia in 76%, and grade 3-4 thrombocytopenia in 58%. No neurotoxicity was observed. HD-MTX can be safely used with supportive care and monitoring.

Journal Title

Pediatric blood & cancer

Volume

71

Issue

10

First Page

31213

Last Page

31213

MeSH Keywords

Humans; Methotrexate; Female; Central Nervous System Neoplasms; Male; Child, Preschool; Antimetabolites, Antineoplastic; Infant; Child; Follow-Up Studies; Retrospective Studies; Prognosis; Mucositis; Neutropenia

Keywords

CNS tumors; children; methotrexate; toxicity

Link to Full Text
Library Record

Share

COinS